echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > 125 pharmaceutical companies half-yearly report forecast out Ofae bioQ2 100 times month-on-month growth.

    125 pharmaceutical companies half-yearly report forecast out Ofae bioQ2 100 times month-on-month growth.

    • Last Update: 2020-08-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    As the current domestic epidemic is still partial lying repeatedly, the global epidemic has not yet ended, therefore, in the market uncertainty caused by the outbreak, the pharmaceutical sector has a relative certainty, which can be reflected in the performance of pharmaceutical enterprises.
    pharmaceutical sector has risen about 49% (60 stocks doubled) so far this year, second only to leisure services, its valuation is still in a high state, including vaccines and other biological products, chemical sized drugs are 142 times, 66 times.
    in the long run, the bull market in the pharmaceutical industry still has good support for three reasons: the domestic macroeconomic environment has undergone subtle changes, the domestic economy is mainly circular;
    at the same time, along with the reduction of most areas of the country risk areas, the outbreak control is good, pharmaceutical enterprises after the resumption of sales, production and other pressures gradually released.
    improved from the previous quarter to 2020Q2.
    of the 125 enterprises that have announced their first-half results, 65 pharmaceutical manufacturing companies have published their half-yearly report forecast, separating their Q1/Q2 two quarters of data, we can see that the performance of pharmaceutical enterprises related to the epidemic in the second quarter to achieve rapid growth, including the demand to enhance the larger vaccine, nucleic acid testing, API enterprises and other industries.
    some enterprises in other areas, although still year-on-year decline, but increased or decreased month-on-month, the overall improvement was significant.
    this can effectively explain that the effect of resumption of production and the epidemic levelled off, the performance of the pharmaceutical industry into a gradual recovery stage.
    biological drugs (non-recurrent profit and loss) can be seen from the chart above, the current 15 have published half-year forecast of biopharmaceutical enterprises, 11 q2 compared to Q1 growth, the proportion of 73.3%.
    demonstrates that biopharmaceuticals recovered faster in the second quarter. The purpose of the reform of the
    payment end is mainly to optimize the industrial structure, including teng-no-generic generic high-price space to promote the development of innovative drugs, resulting in structural market conditions in the pharmaceutical industry.
    the innovation industry chain, which supports strong policy support, may lead the industry for a long time.
    also, as revealed at last week's meeting of the relevant departments of the State Administration of Health Care, biological products (including insulin) and the centralized procurement of traditional Chinese medicine have been put on the agenda.
    with the continuous deepening of the procurement of chemical tape, the expansion of the range of collection to biological drugs is an inevitable trend, but also the continuous deepening of the reform of the payment side of medical insurance.
    expects that the second half of 2020 to full year 2021, the short-term may lead to market sentiment fluctuations but not change the long-term high business climate of the pharmaceutical industry.
    Gan Li Pharmaceuticals was established in 1998 and is a leader in the domestic insulin industry.
    as the first enterprise in China to master the industrial production and restructuring of insulin analogue technology, in recent years, the steady growth of operating income, insulin glargine, insulin products as the main support, market share is also year-on-year growth, in 2019, to achieve operating income of 2.895 billion yuan, up 21.26% YoY;
    2020 Q1 due to the outbreak has been affected by some, but Q2 gradually in a state of rapid recovery, rough estimate q2 q2, Gan Li realized revenue should be between 150 million yuan- and 187 million yuan.
    's overall profit for 2020 is expected to be around 1.333 billion yuan, achieving a 14% increase in net profit.
    at present, Ganli Pharmaceuticals relies on its master of the three-generation insulin core technology, is the first domestic manufacturers with both insulin glargine and mendong insulin.
    in addition to Tonghua Dongbao and the Federal Pharmaceutical, other domestic enterprises are relatively backward in progress, the overall market pattern is good, import substitution advantage is obvious.
    and coincides with last week's State Health Care Administration of the relevant division of the department held a symposium revealed the news, biological products (including insulin) and traditional Chinese medicine centralized procurement work has been put on the agenda, insulin collection may become a domestic insulin alternative imported varieties of market opportunities, is expected to benefit the development of domestic insulin leading enterprises.
    Fourth Ring Biology On July 10, Jiangsu Four Ring Biological Co., Ltd. issued a half-year results forecast for 2020, with a expected net profit of 6.2 million yuan, up 166.14 percent year-on-year.
    but compared with the first quarter report of Four Ring Bio, learned that its Q1 net profit of 10.31 million yuan, that is, four-ring biological in the second quarter of 2020 to achieve net profit should be a loss of 3.8 million yuan, while Q1 quarter to achieve profit growth is also the main reason for the "sale of forest assets."
    , on June 30, Four Rings once again received an inquiry letter from the Shenzhen Stock Exchange's annual report.
    , like the annual report inquiry received last year (the 2018 annual report inquiry), the Shenzhen Stock Exchange has also asked about its sales costs. high sales costs
    remain the biggest problem for the four-ring edited creatures.
    sales expenses from 2016 to 2019 were RMB105.6 million, RMB168.2 million, RMB 220 million and RMB151.3 million, in turn.
    CRO (non-deductible non-recurring gains and losses) Although China still has a gap in the industrial chain compared to the global level, its competitive advantage is relatively clear, benefiting from the growth of downstream demand at home and abroad, the industry's high business climate continued in the second quarter.
    pre-clinical CRO and CDMO orders locked in early, with high full-year results and no worries.
    of which clinical CRO significantly recovered in Q2, the most noteworthy.
    head of the whole industrial chain integration company and in the industrial chain at a stage with characteristics of the company in the industry the fastest recovery speed, will also be in the future development speed of the industry average.
    drug Mingkang on the evening of July 21, the drug Mingkang announced that the company in the first half of 2020 to achieve revenue of 7.231 billion yuan, an increase of 22.68 percent year-on-year.
    realized net profit attributable to shareholders of listed companies of RMB1.717 billion, up 62.49 percent year-on-year.
    net profit for the April-June period was RMB1.41 billion, up 365.3% month-on-month.
    the reasons for the change in performance, Pharma Mingkang said the company's China laboratory and contract research and development and production business (CDMO) in the second quarter fully resumed normal operations.
    at the same time, with the rapid growth of overseas customer orders, as well as the company's capacity utilization and operating efficiency continue to improve, the company's second quarter operating income achieved strong growth.
    's Clinical Trial Services (CRO) and Field Management Services (SMO) businesses are also in the midst of a gradual recovery since the second quarter.
    as a whole, the drug-mind Kant is one of the industry's leading customers, with more than 70% of its customers coming from the United States and Europe.
    but in the current outbreak of domestic light overseas heavy second quarter, the drug Mingkang can still focus on the layout of overseas customers, the number of orders has also been faster growth, capacity utilization and operating efficiency of the credit is essential, as mentioned above, the head of the whole industrial chain integration company rely on its general amount and layout is extensive, the recovery speed has been confirmed.
    Chinese medicine (non-deductible non-recurring gains and losses) Xinbang Pharmaceuticals on the evening of July 13, Xinbang Pharmaceuticals disclosed earnings forecast, the first half of the pre-earnings of 30 million yuan - 40 million yuan, down 67.03% - 75.27% YoY.
    but compared with the first and second quarters can be found, although affected by the new crown pneumonia and other factors, the company's first quarter operating results showed a loss, since the second quarter, production and operation can be quickly restored, the first half of the year to achieve profits, the first quarter-on-quarter growth of 430.77 percent to 507.69 percent, the first announced mid-year forecast of Chinese medicine enterprises.
    for the reasons for the change in performance, the official announcement shows that since the second quarter, with the domestic epidemic situation gradually under control, as well as a series of national support for the resumption of production and stability of economic policy measures, production and operation can be quickly restored, the first half of the profit.
    in recent years, the policy changes of the pharmaceutical regulatory authorities have brought about major changes in the policy environment of the pharmaceutical industry, with the company's sales and prices of its main products falling and operating performance falling sharply.
    revenue growth rate for fy2017, 2018, fy2019 and first quarter of 2020 was 16.3%, 9.63%, 1.14%, and -20.22%, respectively.
    recently, and fell into the vortex of the reorganization of the assets of the pharmaceutical industry, but also by the shanghai new century into the credit watch list.
    can be described as a disaster.
    pharmaceuticals (non-deductible non-recurring gains and losses) Yuheng Pharmaceuticals issued a earnings forecast on the evening of July 14, and expected to make a first-half profit of 650-680 million yuan, up 179.83 percent-192.75 percent year-on-year.
    but the growth in performance is mainly due to non-recurring gains and losses, during the reporting period confirmed the sale of 100% of Aono (China) Pharmaceutical Co., Ltd., the estimated impact on net profit of about 687 million yuan;
    in fact, the company's second quarter operating results improved, quarter-on-quarter improvement, but the specific figures need to wait for the mid-year statements specifically disclosed.
    , however, the problems facing Yuheng Pharmaceuticals are not as simple as they seem.
    the day before, Yuheng Pharmaceuticalannounced the bankruptcy reorganization of the company's controlling shareholder Yu Heng Group, at present, Yuheng Group has entered the bankruptcy reorganization proceedings.
    caused today's "insolvent" situation is an important reason for the acquisition of Xinbang Pharmaceuticals directly related, but whether it is Xinbang Pharmaceuticals or Yuheng Pharmaceuticals, the stock price trend of the two listed companies is not as expected, Yuheng Group due to the acquisition of Xinbang Pharmaceutical stake and bear a huge financial pressure can not be alleviated, the after-effects of the merger and acquisition are all-round highlighted.
    , Yu Heng Pharmaceuticals attributed to the changes in the policy environment of the pharmaceutical industry brought about by the policy changes of the pharmaceutical regulatory agency, the two-vote policy, medical insurance control fees and other multiple policy factors, the main product sales and prices continue to decline, the sharp decline in operating performance is an important reason for its gradual decline.
    but perhaps, Yuheng Pharmaceuticals did not see the times and the nature of the industry may be the ultimate cause of its merger and acquisition on the road to failure, know the reason, but still do not want to make changes, which is the current generic drug industry is a common problem.
    with the further development of volume procurement, there will be more types of enterprises in the future to repeat the same mistakes.
    no doubt, now in the consistency evaluation, volume procurement, health care payment reform and other forced the entire industry transformation and upgrading background, the market left to Yu Heng Pharmaceuticals such as enterprise transformation time has been limited.
    the advent of the era of micro-profit, only the core competitiveness of products can adapt to market development, perhaps also means that the sooner the layout of innovative drugs and high-end generic drugs, the follow-up advantages will be reflected in it.
    timing, is the current generic drug-like enterprises first need to pay attention to the content.
    look to the future Although the rumors circulate, the bull market has arrived.
    but in recent weeks, the pharmaceutical section volatility, many enterprises share prices and market value has been greatly affected, but on the whole, the pharmaceutical industry as the domestic more needed areas, its market value is still there, in the future the growth of the pharmaceutical industry can still be optimistic, the author believes that there are reasons for this: 1) domestic aging acceleration, pharmaceutical consumption has a new demand nature is certain, the pharmaceutical industry demand is also gradually strong, especially the pursuit of high-quality medical resources is still not changing. 2) Further optimization of the review and approval system, revision of the drug registration management law, generic drug consistency evaluation and other pharmaceutical policy regulation under the supply-side reform, so that the pharmaceutical industry in the industry dynamic stock market restructuring and innovation-driven industry incremental development of steady progress.
    in the belt procurement, health insurance payment structural adjustment under the promotion of the payment side reform, promote the rapid promotion of industry concentration, leading enterprises strong Hengqiang, industry concentrated in the top of the pyramid enterprises, a healthier industrial environment can promote the long-term good development of the pharmaceutical industry;
    at the same time the outbreak also to a certain extent has also raised the public's attention to the pharmaceutical industry, high-end drug research and development will be accelerated.
    investment in new health care infrastructure that complements the health care system will also boost growth in the healthcare and pharmaceutical industries.
    combined with the above point of view, the author expects that in the second half of 2020 investors can still focus on "epidemic prevention and control" "innovation and innovation industry" "raw material syb" "Chinese medicine" four main lines.
    future development trends to a large extent determine the starting point of these industries, of course, the main line under the layout of the head enterprises can not be ignored.
    the "2020 China CRO Company Rankings" election campaign vote into the countdown.
    more than 180 research and development CRO and CDMO companies to participate in the selection, the event visits amounted to 3.07 million plus, the cumulative number of votes 1.15 million plus.
    as of July 22 at 18:00, Baino Pharma with 99,000 votes temporarily led the research and development CRO, the top spot, Kempton, Excellent Future with 59,000 plus votes in the second and third place, and CDMO company popular TOP3 is temporarily for Yuexing Pharmaceuticals, Sino-Peptide Biochemical, Mei Bairui.
    all the way to watch the official, sprint stage, your enthusiasm will be the key to the campaign to reach the peak of the campaign! Quickly scan the next two-dimensional code to participate in the voting, every day for the favorite enterpriseto vote 3, after voting in accordance with the guidelines to participate in the raffle, Huawei mobile phones, tablets, high-end embroidery, professional books... Worth 50,000 yuan, 130 plus jackpots and so on you to take!
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.